MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) announced today at its annual institutional investor and analyst meeting that the company purchased substantially all glucose monitoring assets from PreciSense A/S, a Denmark-based development company focused on continuous glucose monitoring (CGM) technology. Specific terms of the acquisition were not disclosed.
